Department of Radiation Oncology, University of Rochester, Rochester, New York.
Department of Radiation Oncology, University of Rochester, Rochester, New York.
Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):931-943. doi: 10.1016/j.ijrobp.2022.11.012. Epub 2023 Jan 20.
We sought to systematically review and summarize dosimetric factors associated with radiation-induced brachial plexopathy (RIBP) after stereotactic body radiation therapy (SBRT) or hypofractionated image guided radiation therapy (HIGRT). From published studies identified from searches of PubMed and Embase databases, data quantifying risks of RIBP after 1- to 10-fraction SBRT/HIGRT were extracted and summarized. Published studies have reported <10% risks of RIBP with maximum doses (D) to the inferior aspect of the brachial plexus of 32 Gy in 5 fractions and 25 Gy in 3 fractions. For 10-fraction HIGRT, risks of RIBP appear to be low with D < 40 to 50 Gy. For a given dose value, greater risks are anticipated with point volume-based metrics (ie, D: minimum dose to hottest 0.03-0.035 cc) versus D. With SBRT/HIGRT, there were insufficient published data to predict risks of RIBP relative to brachial plexus dose-volume exposure. Minimizing maximum doses and possibly volume exposure of the brachial plexus can reduce risks of RIBP after SBRT/HIGRT. Further study is needed to better understand the effect of volume exposure on the brachial plexus and whether there are location-specific susceptibilities along or within the brachial plexus structure.
我们旨在系统地回顾和总结与立体定向体部放射治疗(SBRT)或低分割图像引导放射治疗(HIGRT)后放射性臂丛神经病(RIBP)相关的剂量学因素。从 PubMed 和 Embase 数据库的搜索中确定了已发表的研究,提取并总结了这些研究中量化 SBRT/HIGRT 单次至 10 次分割后 RIBP 风险的数据。已发表的研究报告称,在 5 次分割中接受 32 Gy 和 3 次分割中接受 25 Gy 的臂丛神经下极最大剂量(D)后,RIBP 的风险<10%。对于 10 次分割的 HIGRT,D < 40 至 50 Gy 时,RIBP 的风险似乎较低。对于给定的剂量值,基于点体积的指标(即 D:最热的 0.03-0.035 cc 的最小剂量)比 D 预计会有更高的风险。对于 SBRT/HIGRT,由于缺乏已发表的数据,因此无法预测与臂丛神经剂量-体积暴露相关的 RIBP 风险。尽量降低 SBRT/HIGRT 后臂丛神经的最大剂量和可能的体积暴露,可以降低 RIBP 的风险。需要进一步研究以更好地了解体积暴露对臂丛神经的影响,以及臂丛神经结构内或周围是否存在特定部位的易感性。